Photo from wikipedia
Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. 9. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma:… Click to show full abstract
Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. 9. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a metaanalysis of individual patient data. Lancet Oncol. 2014;15(3):333-342. 10. Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8): e328-e346. 11. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683-687. 12. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791. 13. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
Journal Title: American Journal of Hematology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!